ArticleFrontiers in immunology2026
Anti-NMDAR encephalitis following malaria: expanding the spectrum of post-malarial neurological syndromes.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common form of autoimmune encephalitis (AIE), often triggered by viral infections or tumors. This report describes a rare case following a parasitic infection. Case findings: We report a rare case of anti-NMDAR encephalitis developing in a 40-year-old man following recovery from Plasmodium falciparum malaria. Despite confirmed parasite clearance, he presented eleven days later with seizures, altered consciousness, and acute psychosis. Anti-NMDAR antibodies were detected in the cerebrospinal fluid (CSF) via both immunofluorescence and cell-based assay, with no evidence of concurrent infection or malignancy. The patient showed rapid clinical improvement after first-line immunotherapy. Conclusion: This report represents the first antibody-confirmed case of anti-NMDAR encephalitis following Plasmodium falciparum infection, highlighting malaria as a novel post-infectious trigger and expanding the recognized spectrum of post-malarial neurological syndromes (PMNS). It underscores that clinicians in endemic regions should maintain a high index of suspicion for AIE in patients with new neuropsychiatric symptoms after malaria and pursue early antibody testing and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.